Solar Eclipse on August 2: NASA update on entire world going in '6 minutes of complete darkness'
solar eclipse
of such magnitude is scheduled for August 2, 2027, not 2025. Here's what you need to know about the buzz around the celestial phenomenon
NASA records show no solar eclipse on August 2, 2025
According to NASA's astronomical data, the next total solar eclipse of this magnitude will occur on August 2, 2027, not in 2025 as suggested by viral claims and rumours spreading online. Further, this event will be a significant celestial occurrence, but it will not darken the entire world.
The eclipse will cast the Moon's shadow over parts of Europe, North Africa, and the Middle East, creating a spectacular but localized event. The rest of the world, including North America and large parts of Asia, will not witness this eclipse at all.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Susan Boyle Is Now so Thin and Looks Beautiful!
5minstory.com
Undo
The August 2, 2027, total solar eclipse is being called the 'Eclipse of the Century' because it will offer the longest duration of totality on land in the 21st century — lasting up to 6 minutes and 22 seconds, the longest since 1991.
The path of totality—the area where the Sun will be completely blocked—will be about 160 miles (258 km) wide, stretching over 9,462 miles (15,227 km) and covering parts of 11 countries, including:
Spain, Gibraltar, Morocco, Algeria, Tunisia, Libya, Egypt, Sudan, Saudi Arabia, Yemen, and Somalia.
For those within this path, the sky will briefly turn dark in broad daylight, creating a dramatic twilight effect. Areas outside this path may see a partial eclipse, but no blackout.
What happens during a total solar eclipse
A total solar eclipse happens when the Moon comes directly between the Earth and the Sun. As a result of this celestial movement, the Sun's light is blocked, casting a shadow on parts of Earth. During totality, viewers see the Sun's corona—its outer atmosphere—which is usually hidden by the Sun's glare.
Total solar eclipses are visible only from a narrow strip of land, and their duration is typically just a few minutes.
Next Solar eclipse on September 21, 2025
While no total eclipse will occur in 2025, a partial solar eclipse is expected on September 21, 2025. During this event, the Moon will partially obscure the Sun, making it appear as though a 'bite' has been taken out of it.
This partial eclipse will not cause darkness, nor will it be visible worldwide.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
31 minutes ago
- Economic Times
Seeds of seabuckthorn, Himalayan buckwheat part of experiment on ISS
Reuters NASA's SpaceX Crew-11 crew members (File photo) Seeds of seabuckthorn and buckwheat grown in the cold desert of Ladakh are part of the experiments on board the International Space Station flown by NASA's Crew-11 mission. Seeds procured from 11 nations across five continents are part of the study spearheaded by US-based bioastronautics firm Jaguar Space, which plans to expose the seeds to microgravity conditions for a week. The seeds are part of the "Emerging Space Nation's Space for Agriculture & Agriculture for Space" payload that flew to the ISS along with NASA's Crew-11, which lifted off from Florida on Friday and docked onto the orbital lab on seeds will be brought back by the Crew-10, which is expected to return to Earth later this month. The seeds grown in Ladakh were sourced by Bengaluru-based space start-up Protoplanet. "We will study how the seeds react to micro-gravity conditions and their potential use as a food source for long-duration space missions," Siddharth Pandey, Director, Protoplanet, told stated that Protoplanet has contributed sea buckthorn and Himalayan tartary, nutrient-rich plants native to high-altitude regions. The Himalayan tartary is a variety of buckwheat that is nutrient-rich and return from space, the seeds will be studied by Indian to Jaguar Space, the World Seeds study examines how seeds react to the unique stresses of the space environment before they begin to grow, focusing on fundamental processes such as the activation of genes and metabolic pathways essential for germination. This experiment explores the potential of previously unexamined species to contribute to future space agriculture initiatives. Seeds from the Maldives, Argentina, Brazil, Costa Rica, Guatemala, Nigeria, Armenia, Egypt, Pakistan and Nigeria are part of the experiment. "Beyond its scientific potential to advance research on climate resilience and global food security, the World Seeds payload represents a meaningful step toward ensuring that, as humanity becomes a spacefaring civilization, the millennia-old knowledge, biodiversity, and cultural heritage of communities around the world are carried forward as an essential part of that journey," said Dr Luis Zea, Founder of Jaguar Space.
Deccan Herald
an hour ago
- Deccan Herald
Seeds of seabuckthorn, Himalayan buckwheat part of experiment on ISS
The seeds are part of the 'Emerging Space Nation's Space for Agriculture & Agriculture for Space' payload that flew to the ISS along with NASA's Crew-11.
Time of India
an hour ago
- Time of India
Cancer cure? Russia commences human trials of revolutionary personalized cancer vaccine
In a landmark advancement for oncology and personalized medicine, Russia's Gamaleya National Research Center of Epidemiology and Microbiology—the creators of the Sputnik V COVID-19 vaccine—announced this year that it will begin human clinical trials of the world's first personalized mRNA-based melanoma vaccine within the next few months. Alexander Gintsburg, director of the Gamaleya Center, confirmed that this groundbreaking vaccine, tailored specifically to the genetic profile of individual patients' tumors, will start experimental administration as early as September-October 2025 in collaboration with leading Russian oncology institutions . Explore courses from Top Institutes in Please select course: Select a Course Category Cybersecurity CXO others Public Policy Healthcare Digital Marketing Degree MBA Artificial Intelligence Others PGDM Data Science Data Analytics Product Management MCA Operations Management Leadership Design Thinking Project Management Finance Management healthcare Technology Data Science Skills you'll gain: Duration: 10 Months MIT xPRO CERT-MIT xPRO PGC in Cybersecurity Starts on undefined Get Details Q. What are melanoma cells by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 15 most beautiful women in the world Undo A. Melanoma cells come from melanocytes, the skin cells that give it color. When these cells grow too much and become cancerous, they cause melanoma, a dangerous kind of skin cancer that can spread fast if not treated early. Q. What is mRNA, and how is it used in vaccines? A. mRNA, or messenger RNA, is a molecule that carries genetic instructions from DNA to the cell's protein-making machinery. It acts like a messenger, conveying the code needed to build specific proteins that perform various functions in the body. In vaccines, mRNA teaches cells to produce a harmless piece of a virus or cancer antigen, triggering the immune system to respond and protect the body. Live Events This novel cancer vaccine is designed to train the immune system to recognize and attack melanoma cells by creating a bespoke mRNA blueprint derived from each patient's unique tumor mutations. The process involves sophisticated artificial intelligence algorithms that analyze the tumor's genetic data to produce a molecular template, which is then synthesized at Gamaleya's production facilities. This tailor-made mRNA encodes proteins that activate a targeted cytotoxic immune response, aiming not only to eradicate primary tumors but also to address metastatic cancer sites. Gintsburg elaborated that the entire vaccine development cycle—from tumor sequencing to vaccine production—can be completed within about one week due to AI-assisted mathematical modeling and neural network computing. This rapid manufacture represents a significant leap compared to typical timelines in personalized cancer therapies. Q. What is a personalized cancer vaccine? A. Personalized cancer vaccine is a tailored immunotherapy designed to train the patient's immune system to recognize and attack their specific cancer cells. It uses information from the patient's tumor genetics to create a unique vaccine that targets tumor-specific mutations, differing from general vaccines. The vaccine model was developed starting in mid-2022 and has already demonstrated promising efficacy in preclinical animal studies, showing the ability to suppress tumor growth and reduce metastasis. The upcoming Phase I clinical trials will take place at two of Russia's foremost oncology centers: the Hertsen Research Institute and the N.N. Blokhin National Medical Research Center of Oncology in Moscow. Importantly, this tailored vaccine is part of a wider Russian initiative to advance cancer treatment across various difficult-to-treat types, including pancreatic, kidney, and non-small-cell lung cancers. The Russian Ministry of Health classifies this vaccine development and approval under a new, specialized regulatory process recognizing its individualized nature, differing fundamentally from traditional drug registration. The state plans to provide this cancer vaccine free of charge to Russian citizens, with an estimated production cost of around 300,000 rubles (approx. USD 2,869) per dose covered by government funding. According to health authorities, about 4 million Russians live with cancer, and approximately 625,000 new cancer cases are diagnosed annually, underlining the urgent need for innovative therapies. The vaccine's success could mark a pivotal moment in Russia's fight against cancer and elevate its personalized medicine program. Unlike the COVID-19 mRNA vaccines designed to target a single viral antigen, this personalized cancer vaccine encodes multiple neoantigens specific to each patient's tumor, offering a multi-targeted immune approach.
